Efficacy and safety measures for low density lipoprotein apheresis treatment using dextran sulfate cellulose columns.
Long-term low density lipoprotein (LDL) apheresis using dextran sulfate cellulose (DSC) columns is a well tolerated treatment for drug refractory hypercholesterolemia with coronary heart disease (CHD). Hypercholesterolemic patients may benefit from LDL apheresis combined with cholesterol lowering drug therapy in terms of the prevention of the progression of atherosclerosis, stabilization of atheromatous plaque, and reduction of cardiac events. The major adverse reaction of LDL apheresis is temporal hypotension caused by hypovolemia or vasovagal reactions due to extracorporeal circulation. Anaphylactoid reactions in patients administered angiotensin converting enzyme inhibitors (ACE-I) are other dextran sulfate cellulose column related adverse reactions, which must be carefully prevented by ceasing the administration of ACE-I before LDL apheresis treatment. ACE-I must not be administered to patients undergoing LDL apheresis.
Koga
N
N
Shin-Koga Hospital, Kurume City, Japan.
D001781:Blood Component Removal / Q000009:adverse effects / Q000379:methods; D002482:Cellulose; D016264:Dextran Sulfate; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000628:therapy*; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000628:therapy*; D008077:Lipoproteins, LDL / Q000097:blood*
D008077:Lipoproteins, LDL; D002482:Cellulose; D016264:Dextran Sulfate